Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

奥拉帕尼 医学 肿瘤科 仿形(计算机编程) 内科学 癌症研究 精密医学 精确肿瘤学 癌症 临床试验 实体瘤 靶向治疗 队列
作者
Daniel Ricardo Carrizosa,Michael Rothe,Pam K. Mangat,Elizabeth S. Garrett-Mayer,Deepti Behl,Bamidele A. Adesunloye,Evan P. Pisick,Kathleen W. Beekman,Efrat Dotan,Mehmet Akce,Olatunji Boladale Alese,Vaibhav Sahai,Kelsey A. Klute,Jeanny B. Aragon‐Ching,Kathrine A. Cooper,Ramya Thota,Funda Meric‐Bernstam,Peter J. Hosein,Erika Maestas,Justin Tyler Moyers
出处
期刊:JCO precision oncology [Lippincott Williams & Wilkins]
卷期号:10 (1): e2500716-e2500716 被引量:3
标识
DOI:10.1200/po-25-00716
摘要

PURPOSE The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of targeted agents in patients with advanced cancer and genomic alterations. Results of four cohorts of patients with ATM -altered tumors treated with olaparib are reported: colorectal cancer (CRC), lung cancer (LC), pancreatic cancer (PC), and other solid tumors (histology-pooled, HP). METHODS Eligible patients had advanced solid tumors, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16 weeks duration. For histology-specific cohorts, Simon's two-stage design was based on a null DC rate of 15% versus 35% (power = 0.85; α = .10). For the HP cohort, the hypothesized null DC rate of 15% was rejected if the lower limit of a one-sided 90% CI was >15%. Secondary end points were OR, progression-free survival, overall survival, duration of response or SD, and safety. RESULTS Patients with CRC (n = 30), LC (n = 20), PC (n = 28), or other advanced cancers (n = 38) with ATM alterations were enrolled. The DC rates were 23% (one-sided 90% CI, 8 to 100; P = .38), 45% (one-sided 90% CI, 32 to 100; P = .0004), 28% (one-sided 90% CI, 14 to 100; P = .14), and 25% (one-sided 90% CI, 16 to 100), respectively. The null hypothesized 15% DC rate was rejected for the LC and HP cohorts but not the CRC and PC cohorts. Twenty of 116 patients (17%) experienced treatment-related grade 3 adverse events (AE) or serious AEs. CONCLUSION Olaparib met the prespecified criteria to declare a signal of activity in patients with ATM -altered cancer within the LC and HP cohorts but not the CRC or PC cohorts.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
xixi完成签到,获得积分10
刚刚
1秒前
yuxin完成签到 ,获得积分10
1秒前
Owen的应助被快乐的大傻采纳,获得10
1秒前
dora完成签到,获得积分10
1秒前
1秒前
2秒前
夏洳完成签到,获得积分10
2秒前
2秒前
Debbie的应助被huo采纳,获得10
2秒前
night完成签到,获得积分10
2秒前
LION发布了新的文献求助50
3秒前
追悟完成签到,获得积分10
3秒前
3秒前
留胡子的凌寒完成签到 ,获得积分10
3秒前
sghsh完成签到,获得积分20
3秒前
kmkz完成签到,获得积分10
4秒前
无花果的应助被西红柿采纳,获得10
4秒前
Helium发布了新的文献求助10
5秒前
123发布了新的文献求助10
6秒前
忧郁平蝶完成签到,获得积分10
6秒前
sghsh发布了新的文献求助20
6秒前
冷静的夏槐完成签到,获得积分10
6秒前
6秒前
wanci的应助被tao采纳,获得10
7秒前
海砂发布了新的文献求助10
7秒前
7秒前
7秒前
YUAN完成签到,获得积分20
7秒前
7秒前
追逐梦想的打工人完成签到,获得积分10
8秒前
cdc完成签到 ,获得积分10
8秒前
8秒前
淡定的静枫完成签到,获得积分10
8秒前
qian发布了新的文献求助10
8秒前
一米阳光发布了新的文献求助10
8秒前
jzhou65发布了新的文献求助10
9秒前
枫楠完成签到,获得积分10
9秒前
斯文败类的应助被俊秀的火车采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160467
求助须知:如何正确求助?哪些是违规求助? 9555463
关于积分的说明 21728123
捐赠科研通 7750270
什么是DOI,文献DOI怎么找? 3427393
关于科研通互助平台的介绍 2552425
邀请新用户注册赠送积分活动 2471741